Literature DB >> 28893493

Brain TSPO imaging and gray matter volume in schizophrenia patients and in people at ultra high risk of psychosis: An [11C]PBR28 study.

Sudhakar Selvaraj1, Peter S Bloomfield2, Bo Cao3, Mattia Veronese4, Federico Turkheimer4, Oliver D Howes5.   

Abstract

Patients with schizophrenia show whole brain and cortical gray matter (GM) volume reductions which are progressive early in their illness. Microglia, the resident immune cells in the CNS, phagocytose neurons and synapses. Some post mortem and in vivo studies in schizophrenia show evidence for elevated microglial activation compared to matched controls. However, it is currently unclear how these results relate to changes in cortical structure.
METHODS: Fourteen patients with schizophrenia and 14 ultra high risk for psychosis (UHR) subjects alongside two groups of age and genotype matched healthy controls received [11C]PBR28 PET scans to index TSPO expression, a marker of microglial activation and a 3T MRI scan. We investigated the relationship between the volume changes of cortical regions and microglial activation in cortical GM (as indexed by [11C]PBR28 distribution volume ratio (DVR).
RESULTS: The total cortical GM volume was significantly lower in SCZ than the controls [mean (SD)/cm3: SCZ=448.83 (39.2) and controls=499.6 (59.2) (p=0.02) but not in UHR (mean (SD)=503.06 (57.9) and controls=524.46 (45.3) p=0.3). Regression model fitted the total cortical GM DVR values with the cortical regional volumes in SCZ (r=0.81; p<0.001) and in UHR (r=0.63; p=0.02). We found a significant negative correlation between the TSPO signal and total cortical GM volume in SCZ with the highest absolute correlation coefficient in the right superior-parietal cortex (r=-0.72; p=0.006).
CONCLUSIONS: These findings suggest that microglial activity is related to the altered cortical volume seen in schizophrenia. Longitudinal investigations are required to determine whether microglial activation leads to cortical gray matter loss.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Brain volume; Gray matter; Microglia; PET; Psychosis; Schizophrenia

Mesh:

Substances:

Year:  2017        PMID: 28893493      PMCID: PMC6027955          DOI: 10.1016/j.schres.2017.08.063

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  99 in total

Review 1.  Plasma radiometabolite correction in dynamic PET studies: Insights on the available modeling approaches.

Authors:  Matteo Tonietto; Gaia Rizzo; Mattia Veronese; Masahiro Fujita; Sami S Zoghbi; Paolo Zanotti-Fregonara; Alessandra Bertoldo
Journal:  J Cereb Blood Flow Metab       Date:  2015-10-14       Impact factor: 6.200

2.  Imaging microglial/macrophage activation in spinal cords of experimental autoimmune encephalomyelitis rats by positron emission tomography using the mitochondrial 18 kDa translocator protein radioligand [¹⁸F]DPA-714.

Authors:  Galith Abourbeh; Benoit Thézé; Renaud Maroy; Albertine Dubois; Vincent Brulon; Yoann Fontyn; Frédéric Dollé; Bertrand Tavitian; Raphaël Boisgard
Journal:  J Neurosci       Date:  2012-04-25       Impact factor: 6.167

3.  The effect of atypical antipsychotics, perospirone, ziprasidone and quetiapine on microglial activation induced by interferon-gamma.

Authors:  Qian Bian; Takahiro Kato; Akira Monji; Sadayuki Hashioka; Yoshito Mizoguchi; Hideki Horikawa; Shigenobu Kanba
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2007-07-05       Impact factor: 5.067

4.  Increase in HLA-DR immunoreactive microglia in frontal and temporal cortex of chronic schizophrenics.

Authors:  K Radewicz; L J Garey; S M Gentleman; R Reynolds
Journal:  J Neuropathol Exp Neurol       Date:  2000-02       Impact factor: 3.685

5.  Imaging neuroinflammation in gray and white matter in schizophrenia: an in-vivo PET study with [18F]-FEPPA.

Authors:  Miran Kenk; Thiviya Selvanathan; Naren Rao; Ivonne Suridjan; Pablo Rusjan; Gary Remington; Jeffrey H Meyer; Alan A Wilson; Sylvain Houle; Romina Mizrahi
Journal:  Schizophr Bull       Date:  2014-11-09       Impact factor: 9.306

6.  In Vivo Detection of Diffuse Inflammation in Secondary Progressive Multiple Sclerosis Using PET Imaging and the Radioligand ¹¹C-PK11195.

Authors:  Eero Rissanen; Jouni Tuisku; Johanna Rokka; Teemu Paavilainen; Riitta Parkkola; Juha O Rinne; Laura Airas
Journal:  J Nucl Med       Date:  2014-04-07       Impact factor: 10.057

Review 7.  Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders.

Authors:  Rainer Rupprecht; Vassilios Papadopoulos; Gerhard Rammes; Thomas C Baghai; Jinjiang Fan; Nagaraju Akula; Ghislaine Groyer; David Adams; Michael Schumacher
Journal:  Nat Rev Drug Discov       Date:  2010-12       Impact factor: 84.694

8.  Progressive brain structural changes mapped as psychosis develops in 'at risk' individuals.

Authors:  Daqiang Sun; Lisa Phillips; Dennis Velakoulis; Alison Yung; Patrick D McGorry; Stephen J Wood; Theo G M van Erp; Paul M Thompson; Arthur W Toga; Tyrone D Cannon; Christos Pantelis
Journal:  Schizophr Res       Date:  2009-01-12       Impact factor: 4.939

9.  Translocator protein (18 kDa) (TSPO) is expressed in reactive retinal microglia and modulates microglial inflammation and phagocytosis.

Authors:  Marcus Karlstetter; Caroline Nothdurfter; Alexander Aslanidis; Katharina Moeller; Felicitas Horn; Rebecca Scholz; Harald Neumann; Bernhard H F Weber; Rainer Rupprecht; Thomas Langmann
Journal:  J Neuroinflammation       Date:  2014-01-08       Impact factor: 8.322

10.  In vivo markers of inflammatory response in recent-onset schizophrenia: a combined study using [(11)C]DPA-713 PET and analysis of CSF and plasma.

Authors:  J M Coughlin; Y Wang; E B Ambinder; R E Ward; I Minn; M Vranesic; P K Kim; C N Ford; C Higgs; L N Hayes; D J Schretlen; R F Dannals; M Kassiou; A Sawa; M G Pomper
Journal:  Transl Psychiatry       Date:  2016-04-12       Impact factor: 6.222

View more
  14 in total

1.  Biomarker Localization, Analysis, Visualization, Extraction, and Registration (BLAzER) Methodology for Research and Clinical Brain PET Applications.

Authors:  Fabio Raman; Sameera Grandhi; Charles F Murchison; Richard E Kennedy; Susan Landau; Erik D Roberson; Jonathan McConathy
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

2.  PET Imaging of the P2X7 Ion Channel with a Novel Tracer [18F]JNJ-64413739 in a Rat Model of Neuroinflammation.

Authors:  Tamara Berdyyeva; Chunfang Xia; Natalie Taylor; Yingbo He; Gang Chen; Chaofeng Huang; Wei Zhang; Hartmuth Kolb; Michael Letavic; Anindya Bhattacharya; Anna Katrin Szardenings
Journal:  Mol Imaging Biol       Date:  2019-10       Impact factor: 3.488

Review 3.  (Micro)Glia as Effectors of Cortical Volume Loss in Schizophrenia.

Authors:  Allyson P Mallya; Ariel Y Deutch
Journal:  Schizophr Bull       Date:  2018-08-20       Impact factor: 9.306

Review 4.  Lumateperone tosylate, A Selective and Concurrent Modulator of Serotonin, Dopamine, and Glutamate, in the Treatment of Schizophrenia.

Authors:  Kunal Maini; Janice W Hollier; Haley Gould; Victoria Bollich; John John LaForge; Elyse M Cornett; Amber N Edinoff; Adam M Kaye; Alan D Kaye
Journal:  Health Psychol Res       Date:  2021-06-19

5.  TSPO expression and brain structure in the psychosis spectrum.

Authors:  Sina Hafizi; Elisa Guma; Alex Koppel; Tania Da Silva; Michael Kiang; Sylvain Houle; Alan A Wilson; Pablo M Rusjan; M Mallar Chakravarty; Romina Mizrahi
Journal:  Brain Behav Immun       Date:  2018-06-12       Impact factor: 7.217

Review 6.  Effects of Antipsychotic Drugs: Cross Talk Between the Nervous and Innate Immune System.

Authors:  Ayushi Anna Dinesh; Juned Islam; Javad Khan; Federico Turkheimer; Anthony C Vernon
Journal:  CNS Drugs       Date:  2020-09-25       Impact factor: 5.749

7.  Predictive validity of conversion from the clinical high risk syndrome to frank psychosis.

Authors:  Laura A Yoviene Sykes; Maria Ferrara; Jean Addington; Carrie E Bearden; Kristin S Cadenhead; Tyrone D Cannon; Barbara A Cornblatt; Diana O Perkins; Daniel H Mathalon; Larry J Seidman; Ming T Tsuang; Elaine F Walker; Thomas H McGlashan; Kristen A Woodberry; Albert R Powers; Allison N Ponce; John D Cahill; Jessica M Pollard; Vinod H Srihari; Scott W Woods
Journal:  Schizophr Res       Date:  2019-12-19       Impact factor: 4.939

8.  Increased synapse elimination by microglia in schizophrenia patient-derived models of synaptic pruning.

Authors:  Carl M Sellgren; Jessica Gracias; Bradley Watmuff; Jonathan D Biag; Jessica M Thanos; Paul B Whittredge; Ting Fu; Kathleen Worringer; Hannah E Brown; Jennifer Wang; Ajamete Kaykas; Rakesh Karmacharya; Carleton P Goold; Steven D Sheridan; Roy H Perlis
Journal:  Nat Neurosci       Date:  2019-02-04       Impact factor: 24.884

Review 9.  PET Evaluation of Microglial Activation in Non-neurodegenerative Brain Diseases.

Authors:  Christine Ghadery; Laura A Best; Nicola Pavese; Yen Foung Tai; Antonio P Strafella
Journal:  Curr Neurol Neurosci Rep       Date:  2019-05-28       Impact factor: 5.081

10.  Clozapine Prevents Poly (I:C) Induced Inflammation by Modulating NLRP3 Pathway in Microglial Cells.

Authors:  Vijayasree V Giridharan; Giselli Scaini; Gabriela D Colpo; Tejaswini Doifode; Omar F Pinjari; Antônio L Teixeira; Fabricia Petronilho; Danielle Macêdo; João Quevedo; Tatiana Barichello
Journal:  Cells       Date:  2020-02-28       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.